This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

by Steven R. Levin and Robin L. Brey, 147 pp, with illus, $59.95, Woburn, Mass, Butterworth-Heinemann, 2000.

Arch Neurol. 2002;59:650-651.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

This well-structured overview of literature concerning molecular characteristics and clinical consequences of antiphospholipid (APL) antibodies reflects a recent, exponential development of an interdisciplinary field that began with scattered observations in the early 20th century. Chronological descriptions of discoveries are incorporated into relevant chapters on basic science and clinical studies, and explain the historical and immunological relationships between anticardiolipin antibodies and lupus anticoagulant, now both included in the large group of APL antibodies. The review of data reveals the complexity of the subject because of the heterogeneity of APL antibodies, with increasingly recognized diversity in antigenic specificities and in possible effector mechanisms, which often lead to multiple and interrelated clinicopathological events. The mechanism of production and pathogenic significance of APL immunoglobulins also varies. Antiphospholipid antibodies of the immunoglobulin (Ig) G isotype can arise by a primary mechanism and be associated with antiphospholipid syndrome (APS), presenting with recurrent arterial or venous thrombosis . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?